Aspire biopharma, inc., and powerup acquisition corp. announce business combination agreement to create nasdaq-listed biopharmaceutical company driving breakthrough innovations in fda approved drugs, nutraceuticals and supplements

Highlights transaction valuation: the transaction values aspire biopharma, inc. at a pre-money equity value of approximately $316 million. industry-leading platform: aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of “do no harm” fda approved drugs, nutraceuticals and supplements.
NDAQ Ratings Summary
NDAQ Quant Ranking